PCSK9 抑制剂：在 CKD 中是否已准备好成为主流治疗方法？
PCSK9 inhibition: ready for prime time in CKD?
机构信息
Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK; Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
出版信息
Kidney Int. 2018 Jun;93(6):1267-1269. doi: 10.1016/j.kint.2018.01.030.
Lowering LDL cholesterol reduces the risk of atherosclerotic vascular disease in a wide range of patients with chronic kidney disease, with no evidence of a threshold below which further reductions no longer reduce risk. Statins safely lower LDL cholesterol, but novel inhibitors of proprotein convertase subtilisin kexin 9 (PCSK9) provide additional reductions which may reduce atherosclerotic vascular disease yet further in this high risk population.
降低 LDL 胆固醇可降低患有慢性肾脏病的广泛患者发生动脉粥样硬化性血管疾病的风险，并无证据表明存在 LDL 胆固醇进一步降低不再降低风险的下限。他汀类药物可安全降低 LDL 胆固醇，但新型前蛋白转化酶枯草溶菌素 9（PCSK9）抑制剂可提供进一步降低 LDL 胆固醇的作用，从而可能进一步降低该高危人群的动脉粥样硬化性血管疾病风险。
Zotero 插件